145 related articles for article (PubMed ID: 25997714)
21. The presence of cancerous nodules in lymph nodes is a novel indicator of distant metastasis and poor survival in patients with papillary thyroid carcinoma.
Chen L; Zhu Y; Zheng K; Zhang H; Guo H; Zhang L; Wu K; Kong L; Ruan W; Hu J; Zhang X; Chen X
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1035-1042. PubMed ID: 28204971
[TBL] [Abstract][Full Text] [Related]
22. Hashimoto's Thyroiditis Does Not Affect Ultrasonographical, Cytological, and Histopathological Features in Patients with Papillary Thyroid Carcinoma.
Baser H; Ozdemir D; Cuhaci N; Aydin C; Ersoy R; Kilicarslan A; Cakir B
Endocr Pathol; 2015 Dec; 26(4):356-64. PubMed ID: 26481630
[TBL] [Abstract][Full Text] [Related]
23. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
24. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
Chou CK; Liu RT; Kang HY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28294980
[TBL] [Abstract][Full Text] [Related]
26. No relationship between proliferative activity and the MACIS prognostic scoring system in papillary thyroid carcinoma.
Moreira Leite KR; de Araujo VC; Rezende Meirelles MI; Lopes Costa AD; Camara-Lopes LH
Head Neck; 1999 Oct; 21(7):602-5. PubMed ID: 10487946
[TBL] [Abstract][Full Text] [Related]
27. The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents.
Powers PA; Dinauer CA; Tuttle RM; Francis GL
J Pediatr Endocrinol Metab; 2004 Mar; 17(3):339-43. PubMed ID: 15112910
[TBL] [Abstract][Full Text] [Related]
28. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
29. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Ince S; Arslan N
Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
[TBL] [Abstract][Full Text] [Related]
30. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
Kim MH; Ko SH; Bae JS; Lee SH; Jung CK; Lim DJ; Baek KH; Kim SH; Lee JM; Kang MI; Cha BY
Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
33. High TPOAb Levels (>1300 IU/mL) Indicate Multifocal PTC in Hashimoto's Thyroiditis Patients and Support Total Thyroidectomy.
Dong S; Xia Q; Wu YJ
Otolaryngol Head Neck Surg; 2015 Jul; 153(1):20-6. PubMed ID: 25917667
[TBL] [Abstract][Full Text] [Related]
34. Follicular Variant of Papillary Thyroid Cancer with Bilateral Renal Metastases Discovered Incidentally During Work-Up of Primary Endometrial Cancer: A Rare Occurrence.
Lubana SS; Singh N; Tuli SS; Bashir T; Sachmechi I; Kemeny MM
Am J Case Rep; 2015 Jul; 16():459-68. PubMed ID: 26181765
[TBL] [Abstract][Full Text] [Related]
35. Papillary thyroid carcinoma with exuberant nodular fasciitis-like stroma: treatment outcome and prognosis.
Basu S; Nair N; Shet T; Borges AM
J Laryngol Otol; 2006 Apr; 120(4):338-42. PubMed ID: 16623982
[TBL] [Abstract][Full Text] [Related]
36. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
37. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
[TBL] [Abstract][Full Text] [Related]
38. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
39. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
[TBL] [Abstract][Full Text] [Related]
40. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
